A Prospective, Multicentre Trial to assess the safety & effectiveness of an Everolimus-Eluting Coronary Stent System (PROMUS Element) for the Treatment of a Single De Novo Coronary Artery Long Lesion (24 - 34mm in length)

Trial Profile

A Prospective, Multicentre Trial to assess the safety & effectiveness of an Everolimus-Eluting Coronary Stent System (PROMUS Element) for the Treatment of a Single De Novo Coronary Artery Long Lesion (24 - 34mm in length)

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Registrational; Therapeutic Use
  • Acronyms PLATINUM-LL
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 14 Nov 2012 Last checked against Australian New Zealand Clinical Trials Registry.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top